Clinical Evaluation of Acuity 200 (Fluoroxyfocon A) RGP Contact Lens

Refractive Errors Clinical Trial

— Acuity 200  

Official title:

Clinical Evaluation of Safety and Effectiveness for the Acuity 200 (Fluoroxyfocon A) Rigid Gas Permeable Contact Lens

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03971227
• Other study ID #: AVDR 2019-02 v1.0
• Status: Completed
• Phase: N/A
• Start date: April 1, 2019
• Est. completion date: March 19, 2020

Study information

• Verified date: January 2020
• Source: Acuity Polymers, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this clinical investigation is to collect valid scientific safety and effectiveness data on the Acuity 200 (fluoroxyfocon A) Rigid Gas Permeable Contact Lens, manufactured from a newly developed rigid gas permeable material that is highly permeable to oxygen. The clinical performance data reported from this study is intended to be submitted to the U.S. Food and Drug Administration Center for Devices and Radiological Health (CDRH) in support of a 510(k) premarket notification.

Description:

This is an open-label, multi-center, randomized concurrent-control study with the treatment duration of 90 days. Subjects will be recruited into the study based upon the inclusion and exclusion criteria provided. Eligible subjects will be examined for baseline evaluation and lens fitting. Up to sixty (60) subjects will wear the test contact lenses for daily wear and up to twenty-eight (28) subjects will wear the control contact lenses. The subjects will attend seven scheduled study visits and will undergo standard ophthalmic evaluation for contact lens care. The subjects will be followed for a period of three months (90 days) following dispensing of the Test and Control Device.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: March 19, 2020
• Est. primary completion date: March 19, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Prior to being considered eligible to participate in this study, each subject MUST:

• Be at least 18 years of age as of the date of evaluation.

• Have:

• read the Informed Consent,

• been given an explanation of the Informed Consent,

• indicated an understanding of the Informed Consent and

• signed the Informed Consent Form.

• Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.

• Be a current contact lens wearer.

• Possess wearable and visually functional eyeglasses.

• Be in good general health, based on his/her knowledge.

• Require spectacle lens powers between +10.00 and -10.00 diopters sphere with no more than 2.5 diopters of spectacle refractive astigmatism and be willing to wear lenses in both eyes.

• Have manifest refraction visual acuity equal to or better than 0.10 log MAR (20/25 Snellen) in each eye.

Exclusion Criteria:

Subjects may not be enrolled into the study if ANY of the following apply:

• Subject is wearing lenses in a mono-vision modality and is unwilling to be fit with distance lenses in both eyes. NOTE: Subjects may NOT wear mono-vision lenses at any time during the study as it will interfere with the distance visual acuity measurement.

• Subject appears to exhibit poor personal hygiene (that in the investigator's opinion might prevent safe contact lens wear).

• Subject is currently or within 30 days prior to this study has been an active participant in another clinical study.

• Subject is currently pregnant (to the best of the subject's knowledge), is planning a pregnancy within the next 3 months or is lactating.

• Subject is a member, relative or household member of the office staff, including the investigator(s).

• Subject has a known sensitivity to ingredients used in contact lens care products or over-the-counter lubricants and artificial tears.

• Subject has undergone refractive surgery or is currently receiving or has previously received orthokeratology treatment.

• Subject is aphakic or pseudophakic.

• Subject has ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome lupus erythematosus, scleroderma, keratoconus or type II diabetes.

• Subject has 2.5 diopters or great of corneal astigmatism.

• Use of ocular medications for any reason or systemic medications which might interfere with contact lens wear.

• A known history of corneal hypoesthesia (reduced corneal sensitivity).

• Slit lamp findings that would contraindicate contact lens wear, including but not limited to:

• History of corneal ulcer, corneal infiltrates or fungal infections

• Corneal scars within the visual axis

• Pterygium

• Dry eye symptoms with decrease tear levels and punctate staining = Grade 2

• Neovascularization or ghost vessels =l.5 mm in from the limbus

• Seborrhoeic eczema, seborrhoeic conjunctivitis

• History of papillary conjunctivitis that has interfered with lens wear or a current condition of Grade 2 (Mild) or greater

• Clinically significant (Grade 3 or 4) anterior segment abnormalities or any infection of the eye, lids, or associated structures.

• The investigator for any reason considers that it is not in the best interest of the subject to participate in the study.

To be eligible to be randomized for study product trial a subject must have ALL of the inclusion criteria and NONE of the exclusion criteria present. To be eligible for lens dispensing, the subject's study device contact lens visual acuity must be equal to or better than 0.20 log MAR (20/32 Snellen) in each eye

-

Related Conditions & MeSH terms

• Refractive Errors

Intervention

Device:
• Acuity 200 (Fluoroxyfocon A) contact lens
Daily wear rigid gas permeable contact lens
• Acuity 100 (Hexafocon A) contact lens
Daily wear rigid gas permeable contact lens

Locations

Country	Name	City	State
United States	Cornea and Contact Lens Institute of Minnesota	Edina	Minnesota
United States	Ala Mona Advanced Eye Clinic	Honolulu	Hawaii
United States	Reed Eye Associates	Pittsford	New York

Sponsors (2)

Lead Sponsor	Collaborator
Acuity Polymers, Inc.	Andre Vision and Device Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual Acuity	Comparison of the corrected visual acuity (logMAR) between the Test and Control lens. The working hypothesis is that the visual acuity results will be substantially equivalent between the Test and the Control lenses.	90 days
Primary	Slit Lamp Exam Observations	Comparison of slit lamp exam findings (scored from 0-4) between Test and Control arms. The working hypothesis is that the findings will be substantially equivalent between the Test and the Control lenses.	90 days
Primary	Adverse Events	Comparison of the number of device related adverse events in the Test and Control arms. The working hypothesis is that the number of adverse events will be substantially equivalent between the Test and the Control lenses.	90 days
Secondary	Subjective Symptoms	Comparison of subjective symptoms (scored from 0-5) between Test and Control arms. The working hypothesis is that the symptoms will be substantially equivalent between the Test and the Control lenses.	90 days